Die Plazeboantwort bei funktionellen Magen-Darm-Störungen

Zusammenfassung

Die Plazeboresponse bei funktionellen Magen-Darm-Störungen ist bislang unzureichend erklärt und wird in der Regel entweder mystifiziert oder abgewertet; rationale Ansätze zum Verständnis der Plazebowirkung einer medizinischen oder psychologischen Intervention sind jedoch aus der bisherigen Literatur ableitbar. Wir diskutieren hier drei Theorien, die u. E. viele der beschriebenen Plazeboeffekte erklären können: a) Regression zum Mittelwert (regression to the mean, RTM): Dies können „Messfehler” sein, die durch kleine Stichproben, globale abhängige Variablen, spontane Schwankungen der Symptomatik und andere methodische Gründe entstehen. b) Pavlovsche Konditionierung (PC): Hier entsteht die Plazebowirkung z. B. über erfolgreiche Verknüpfung von Diagnose- und Therapiemaßnahmen in der Vergangenheit (Krankengeschichte) eines Individuums mit Symptombesserung. Stimuli aus dem Umfeld der Behandlung, wie die Verabreichung einer Injektion oder die Farbe einer Tablette (konditionierte Stimuli), bekommen so eine therapeutische Potenz. c) Signal-Entdeckungstheorie (signal detection, SD): Die Manipulation von Erwartungen und Kognitionen der Patienten durch Suggestionen und verbale Instruktionen seitens des medizinischen Heilungssystems verändert die Bereitschaft der Patienten, Symptome als gebessert/verschlechtert zu betrachten, insbesondere dann, wenn dies auf dem Hintergrund eines hohen Rauschpegels geschieht, z. B. bei starken Spontanschwankungen der Symptome. Für alle drei theoretischen Modelle werden Beispiele aus der medizinischen und psychologischen Behandlung von Erkrankungen bzw. der experimentellen Forschung herangezogen, einschließlich neuerer Befunde zu kortikalen Korrelaten der Plazebowirkungen in funktionellen Bildgebungsuntersuchungen. Potenzielle biologische Mechanismen der Plazeboantwort werden diskutiert, einschließlich der Möglichkeit einer genetischen Prädisposition, ein Plazeboresponder zu sein.

Abstract

The placebo response in functional bowel disorders is incompletely understood, and is usually either mystified or down-played; a rational approach to the understanding of the placebo response, however, can be deduced from the scientific literature. We present 3 theories that may explain most of the placebo response in medical and psychological interventions. a) Regression to the Mean (RTM): This refers to “errors” in measuring the outcome of therapies that are due to small samples sizes, global assessment variables, spontaneous variability of symptoms, and other methodological reasons. b) Pavlovian Conditioning (PC): Here the placebo response occurs as the consequence of successful association of diagnostic and therapeutic procedures in the past (illness history) of the individual that resulted in symptom improvement. Stimuli in the context of a treatment can thus gain therapeutic potency (become conditioned stimuli), e. g., the procedure of an injection or the colour of a drug. c) Signal Detection theory (SDT): Manipulation of expectations and cognitions of the patient by suggestions and verbal instructions of the health-care system will change the willingness of the patient to perceive symptoms as improved/worsened, specifically if this happens under “noisy” circumstances, e. g., with high spontaneous variability of symptoms. All three models are illustrated with examples from the medical and psychological treatments or experiments, including recent findings of cortical correlates of the placebo response in functional brain imaging investigations. Potential biological mechanisms for the placebo response are discussed, including he possibility of the genetic predisposition to be a placebo responder.

Plazeboantwort - funktionelle Darmstörungen - Nocebo

Placebo response - functional gastrointestinal disorders - nocebo

Literatur

• 1 Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms.  Neurogastroenterol Mot. 2005;  17 325-330
• 2 Spiller R C. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.  Am J Med. 1999;  107 (Suppl) 91S-97S
• 3 Mearin F, Balboa A, Zarate N. et al . Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses.  Am J Gastroenterol. 1999;  94 116-125
• 4 Allescher H D, Bockenhoff A, Knapp G. et al . Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.  Scand J Gastroenterol. 2001;  36 934-941
• 5 Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle elaxants in the treatment of irritable bowel syndrome.  Aliment Pharmacol Ther. 2001;  15 355-361
• 6 Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.  Neurogastroenterol Motil. 2003;  15 79-86
• 7 Jackson J L, O’Malley P G, Tomkins G. et al . Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.  Am J Med. 2000;  108 65-72
• 8 Spanier J A, Howden C W, Jones M P. A systematic review of alternative therapies in the irritable bowel syndrome.  Arch Intern Med. 2003;  163 265-274
• 9 Klein K B. Controlled treatment trials in the irritable bowel syndrome: a critique.  Gastroenterology. 1988;  95 232-241
• 10 Patel S M, Ock S M, Stason W. et al . The placebo effect in irritable bowel syndrome (IBS) trials: A meta-analysis.  Neurogastroenterol Mot. 2005;  17 332-340
• 11 Pitz M, Cheang M, Bernstein C N. Defining the predictors of the placebo response in irritable bowel syndrome.  Clin Gastroenterol Hepatol. 2005;  3 237-247
• 12 Moayyedi P. Meta-analysis: Can we mix apples with oranges?.  Am J Gastroenterol. 2004;  99 2297-2301
• 13 Enck P, Klosterhalfen S, Kruis W. Factors affecting therapeutic placebo response rates in patients with irritable bowel syndrome.  Nature Clinical Practice Gastroenterol Hepatol. 2005;  2 354-355
• 14 Ilnyckyj A, Shanahan F, Anton P A. et al . Quantification of the placebo response in ulcerative colitis.  Gastroenterology. 1997;  112 1854-1858
• 15 Su C, Lichtenstein G R, Krok K. et al . A meta-analysis of the placebo response rates of remission and response in clinical trials of active Crohn’s disease.  Gastroenterology. 2004;  126 1257-1269
• 16 Moerman D E, Jonas W B. Deconstructing the placebo effect and finding the meaning response.  Ann Intern Med. 2002;  136 471-476
• 17 de Craen A J, Moerman D E, Heisterkamp S H. et al . Placebo effect in the treatment of duodenal ulcer.  Br J Clin Pharmacol. 1999;  48 853-860
• 18 Weihrauch T R, Gauler T C. Placebo - efficacy and adverse effects in controlled clinical trials.  Arzneimittelforschung. 1999;  49 385-393
• 19 Moerman D E. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure.  Med Anthropol Q. 2000;  14 51-72
• 20 Hrobjartsson A, Gotzsche P C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.  N Engl J Med. 2001;  344 1594-1602
• 21 Hrobjartsson A, Gotzsche P C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment.  J Intern Med. 2004;  256 91-100
• 22 Walsh B T, Seidman S N, Sysko R. et al . Placebo response in studies of major depression - variable, substantial, and growing.  JAMA. 2002;  287 1840-1847
• 23 Chey W D, Chey W Y, Heath A T. et al . Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.  Am J Gastroenterol. 2004;  99 2185-2203
• 24 Vase L, Riley J L 3rd, Price D D. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia.  Pain. 2002;  99 443-452
• 25 Robertson C, Idris N R, Boyle P. Beyond classical meta-analysis: can inadequately reported studies be included?.  Drug Discov Today. 2004;  9 924-931
• 26 Benedetti F, Pollo A, Lopiano L. et al . Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/ nocebo responses.  J Neurosci. 2003;  23 4315-4323
• 27 Gordon S, Ameen V, Bagby B. et al . Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy.  Dig Dis Sci. 2003;  48 1317-1323
• 28 Rollman G B. Signal detection theory measurement of pain: a review and critique.  Pain. 1977;  3 187-211
• 29 Allan L G, Siegel S. A signal detection theory analysis of the placebo effect.  Eval Health Prof. 2002;  25 410-420
• 30 Sullivan M D, Katon W J, Russo J E. et al . Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression.  J Am Board Fam Pract. 2003;  16 22-31
• 31 Kaptchuk T J. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance?.  Ann Intern Med. 2002;  136 (11) 817-825
• 32 Vase L, Robinson M E, Verne G N. et al . The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation.  Pain. 2003;  105 17-25
• 33 Verne G N, Robinson M E, Vase L. et al . Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients.  Pain. 2003;  105 223-230
• 34 De Pascalis V, Chiaradia C, Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting.  Pain. 2002;  96 393-402
• 35 Reynaert C, Janne P, Vause M. et al . Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome.  Psychopharmacology (Berl). 1995;  119 449-454
• 36 Roelofs J, ter R iet G, Peters M L. et al . Expectations of analgesia do not affect spinal nociceptive R-III reflex activity: an experimental study into the mechanism of placebo-induced analgesia.  Pain. 2000;  89 75-80
• 37 Pavlov I P. Gesammelte Werke: Über die Physiologie und Pathophysiologie der höheren Nerventätigkeit. L. Pickenhain Würzburg; ERGON Publ 1998
• 38 de Craen A J, Roos P J, de Leonard Vries A. et al . Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness.  BMJ. 1996;  313 1624-1626
• 39 Lindbaek M, Sandvik E, Liodden K. et al . Predictors for the white coat effect in general practice patients with suspected and treated hypertension.  Br J Gen Pract. 2003;  53 (495) 790-793
• 40 Petrovic P, Kalso E, Petersson K M. et al . Placebo and opioid analgesia - imaging a shared neuronal network.  Science. 2002;  295 1737-1740
• 41 Wager T D, Rittling J K, Smith E E. et al . Placebo-induced changes in fMRI in the anticipation and experience of pain.  Science. 2004;  303 1162-1167
• 42 Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia.  J Neurosci. 1999;  19 3639-3648
• 43 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems.  J Neurosci. 1999;  19 484-494
• 44 White P J. Methodological concerns when designing trials for the efficacy of acupuncture for the treatment of pain.  Adv Exp Med Biol. 2004;  546 217-227
• 45 Streitberger K, Kleinhenz J. Introducing a placebo needle into acupuncture research.  Lancet. 1998;  352 364-365
• 46 Streitberger K, Friedrich-Rust M, Bardenheuer H. et al . Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial.  Clin Cancer Res. 2003;  9 2538-2544
• 47 Schneider A, Enck P, Streitberger K. et al .Acpuncture treatment in irritable bowel syndrome. Gut (in press)
• 48 Klosterhalfen S, Rüttgers A, Krumrey E. et al . Pavlovian conditioning of taste aversion using a motion sickness paradigm.  Psychosomatic Medicine. 2000;  62 671-677
• 49 Klosterhalfen S, Kellermann S, Stockhorst U. et al . Latent inhibition of rotation-chair induced nausea in healthy male and female volunteers.  Psychosomatic Med. 2005;  67 335-340
• 50 Stockhorst U, Wiener J A, Klosterhalfen S. et al . Effects of overshadowing on conditioned nausea in cancer patients: an experimental study.  Physiol Behav. 1998;  64 743-753
• 51 Klosterhalfen S, Kellermann S, Pan F. et al . Motion sickness susceptibility: Effects of gender and ethnicity.  Aviat Space Environ Med. 2005;  76 1051-1057
• 52 Talley N J, Locke G R, Lahr B D. et al . Predicting the placebo response in functional dyspepsia.  Gastroenterology. 2005;  128 A466
• 53 Ameen V Z, Heath A T, Chang L. Gender differences in placebo response in patients with diarrhea-predominant irritable bowel syndrome (IBS).  Gastroenterology. 2005;  128 A463
• 54 Kruis W, Thieme C, Weinzierl M. et al . A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.  Gastroenterology. 1984;  87 1-7
• 55 Enck P, Klosterhalfen S, Kruis W. Determinanten der Plazeboresponse beim Reizdarm-Syndrom.  Deutsche Medizinische Wochenschrift. 2005;  130 1934-1937
• 56 de la Fuente-Fernandez R, Ruth T J, Sossi V. et al . Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease.  Science. 2001;  293 1164-1166
• 57 de la Fuente-Fernandez R, Phillips A G, Zamburlini M. et al . Dopamine release in human ventral striatum and expectation of reward.  Behav Brain Res. 2002;  15 359-363
• 58 Benedetti F, Colloca L, Torre E. et al . Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus.  Nature Neurosci. 2004;  7 587-588
• 59 Leuchter A F, Cook I A, Witte E A. et al . Changes in brain function of depressed subjects during treatment with placebo.  Am J Psychiatry. 2002;  159 122-129
• 60 Mayberg H S, Silva J A, Brannan S K. et al . The functional neuroanatomy of the placebo effect.  Am J Psychiatry. 2002;  159 728-737
• 61 Lieberman M D, Jarcho J M, Berman S. et al . The neural correlates of placebo effects: a disruption account.  NeuroImage. 2004;  22 447-455
• 62 Berman S M, Chang L, Suyenobu B. et al . Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.  Gastroenterology. 2002;  123 969-977
• 63 Wood J N, Grafman J. Human prefrontal cortex: processing and representational perspectives.  Nat Rev Neurosci. 2003;  4 139-147
• 64 Hunter A M, LEuchter A F, Morgan M L. et al . Neurophysiological correlates of side effects in normal subjects randomized to venlafaxine or placebo.  Neuropsychopharmacology. 2005;  30 792-799
• 65 Pariente J, White P, Frackowiak R SJ. et al . Expectancy and belief modulate the enuronal sunstrates of pain treated by acupunture.  NeuroImage. 2005;  25 1161-1167
• 66 Remy F, Frankenstein U N, Mincic A. et al . Pain modulates cerebral activity during cognitive performance.  NeuroImage. 2003;  19 655-664
• 67 Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of the brain.  J Comp Physiol Psychol. 1954;  47 419-427
• 68 Harris G C, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neuron in reward seeking. Nature 2005 (in press)
• 69 Siegel J M. Hypocretin (orexin): role in normal behaviour and neuropathology.  Ann Rev Psychol. 2004;  55 125-148
• 70 Mackintosh N J. The psychology of animal learning. London; Academic Press 1974
• 71 Evans D. Suppression of the acute-phase response as a biological mechanism for the placebo effect.  Med Hypoth. 2005;  64 1-7
• 72 Bendesky A, Sonabend A M. On Schleppfuss’ path: the placebo response in human evolution.  Med Hypoth. 2005;  64 414-416
• 73 Shapiro A K, Shapiro E. The placebo: is it much ado about nothing ?. Harrington A The placebo effect. An interdisciplinary exploration Cambridge/London; Harvard University Press 12-36
• 74 Zajicek G. The placebo effect is the healing force of nature.  The Cancer Journal. 1995;  8 44-45
• 75 Sternberg E M. The balance within: The science connecting health and emotions. New York; W. H. Freeman 2000
• 76 Humphrey N. Great expectations: The evolutionary psychology of faith healing and the placebo effect. Hofsten C van, Bäckman C Psychology at the turn of the millenium. Vol 2: Social, Developmental and Clinical Psychology Hove, Sussex; Psychology Press 2002: 225-246
• 77 Hahn R A. The nocebo phenomenon: concept, evidence, and implications for public health.  Prev Med. 1997;  26 607-611
• 78 Benson H. The nocebo effect: history and physiology.  Prev Med. 1997;  26 612-615
• 79 Liccardia G, Senna G, Russo M. et al . Evaluation of the nocebo effect during oral challenge in patients with adverse drug reaction.  J Investig Allergol Clin Immunol. 2004;  14 104-107
• 80 Kasdan M L, Lewis K, Bruner A. et al . The nocebo effect: Do no harm.  J South Orthop Assoc. 1999;  8 108-113
• 81 Bellamy R. Compensation neurosis: financial reward for illness as nocebo.  Clin Orthop Relat Res. 1997;  336 94-106
• 82 Fishbain D A, Goldberg M. The misdiagnosis of conversion disorder in a psychiatric emergency service.  Gen Hosp Psychiatry. 1991;  13 177-181
• 83 Olden K W. Diagnosis of irritable bowel syndrome.  Gastroenterology. 2002;  122 1701-1714
• 84 Flamen M A, Simonsen T, Olsen H. Drug-related information generates placebo and nocebo responses that modify the drug response.  Psychosom Med. 1999;  61 250-255
• 85 Johanson O, Brox J, Flamen M A. Placebo and nocebo responses, cortisol, and circulating beta-endophin.  Psychosom Med. 2003;  65 786-790
• 86 Staats P S, Staats A, Hekmat H. The additive impact of anxiety and a placebo on pain.  Pain Med. 2001;  2 267-279
• 87 Hunter A M, Leuchter A F, Morgan M L. et al . Neurophysiological correlates of side effects in normal subjects randomized to venlafaxine or placebo.  Neuropsyychopharmacology. 2005;  30 792-799
• 88 Barsky A J, Saintfort R, Rogers M P. et al . Nonspecific medication side effects and the nocebo phenomenon.  JAMA. 2002;  287 622-627
• 89 Kobak K A, Feiger A D, Lipsitz J D. Interview Quality and Signal Detection in Clinical Trials.  Am J Psychiatry. 2005;  162 628
• 90 Kobak K A. A comparison of face-to-face and videoconference administration of the Hamilton Depression Rating Scale.  J Telemed Telecare. 2004;  10 231-235

1 Die Begriffe Arzt, Patient, Proband und Versuchsleiter sind geschlechtsneutral zu verstehen.